Prosecution Insights
Last updated: August 06, 2026

Nalpropion Pharmaceuticals LLC

9 pending office actions • 5 art units • 8 examiners • 0 of 9 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days

Portfolio Summary

9
Total Pending OAs
5
Non-Final OAs
4
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

3
Overdue
0
Due this week
2
Due this month
1
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (3)Due ≤ 30 days (2)Due ≤ 60 days (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

2
Hard (22%)
5
Medium (56%)
1
Easy (11%)
1
Unknown (11%)

Rejection Statute Mix

BucketCases
§101 + other1 (11%)
§103 only1 (11%)
§102 only1 (11%)
§112 only1 (11%)
Double-patenting + other3 (33%)
Multi-statute (no §101)1 (11%)
No statute on record1 (11%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

8
Life Sciences
89% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
1
Business / Other
11% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

90 h
Manual time on pending OAs
18 h
Time saved (low, 20%)
31 h
Time saved (mid, 35%)
0.8 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
SCHMITT, MICHAEL J 2 56.6% +21.7%
RAO, SAVITHA M 1 60.8% +29.7%
RICCI, CRAIG D 1 53.4% +52.6%
WEDDINGTON, KEVIN E 1 75.2% +10.1%
BAEK, BONG-SOOK 1 41.7% +69.8%
IVANOVA, SVETLANA M 1 50.7% +51.6%
PECKHAM, RICHARD GRANT 1 67.2% +37.0%
MCMILLIAN, KARA RENITA 1 30.4% +37.9%

Hard Cases (2)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
17717691 Increasing Drug Bioavailability In Naltrexone Therapy RICCI, CRAIG D 34d
18770144 Methods For Administering Weight Loss Medications SCHMITT, MICHAEL J

Interview Candidates (9)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
17739910 Methods for Treating Visceral Fat Conditions SCHMITT, MICHAEL J 79d overdue
17319882 Compositions And Methods For Reducing Food Cravings MCMILLIAN, KARA RENITA 46d overdue
17493160 Methods Of Treating Overweight And Obesity WEDDINGTON, KEVIN E 2d overdue
17336546 Methods For Reducing Binge Or Compulsive Eating IVANOVA, SVETLANA M 9d
17346902 Methods Of Providing Weight Loss Therapy In Patients With Major Depression BAEK, BONG-SOOK 28d
17717691 Increasing Drug Bioavailability In Naltrexone Therapy RICCI, CRAIG D 34d
18770144 Methods For Administering Weight Loss Medications SCHMITT, MICHAEL J
18731965 Compositions And Methods For Reducing Major Adverse Cardiovascular Events RAO, SAVITHA M

Top Art Units

Art UnitApps
1629 2
1611 2
1627 2
1691 1
1623 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18770144 Methods For Administering Weight Loss Medications SCHMITT, MICHAEL J §101DP Non-Final OA Pending Jul 11, 2024
18731965 Compositions And Methods For Reducing Major Adverse Cardiovascular Events RAO, SAVITHA M 1691 §102DP Non-Final OA Pending Jun 03, 2024
17739910 Methods for Treating Visceral Fat Conditions SCHMITT, MICHAEL J 1629 §103DP Non-Final OA 79d overdue Pending May 09, 2022
17717691 Increasing Drug Bioavailability In Naltrexone Therapy RICCI, CRAIG D 1611 §103§112Other Final Rejection 34d Pending Apr 11, 2022
17493160 Methods Of Treating Overweight And Obesity WEDDINGTON, KEVIN E 1629 Other Non-Final OA 2d overdue Pending Oct 04, 2021
17346902 Methods Of Providing Weight Loss Therapy In Patients With Major Depression BAEK, BONG-SOOK 1611 §112Other Final Rejection 28d Pending Jun 14, 2021
17336546 Methods For Reducing Binge Or Compulsive Eating IVANOVA, SVETLANA M 1627 §102 Final Rejection 9d Pending Jun 02, 2021
17335646 Compositions and Methods for Increasing Insulin Sensitivity PECKHAM, RICHARD GRANT 1627 §103§112DPOther Non-Final OA Pending Jun 01, 2021
17319882 Compositions And Methods For Reducing Food Cravings MCMILLIAN, KARA RENITA 1623 §103Other Final Rejection 46d overdue Pending May 13, 2021

Managing Nalpropion Pharmaceuticals LLC's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month